The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Loss of Heterozygosity for Chromosomes 1p and 16q Is an Adverse Prognostic Factor in Favorable-Histology Wilms Tumor: A Report From the National Wilms Tumor Study Group
Abstract
Purpose: To determine if tumor-specific loss of heterozygosity (LOH) for chromosomes 1p or 16q is associated with a poorer prognosis for children with favorable-histology (FH) Wilms tumor entered on the fifth National Wilms Tumor Study (NWTS-5). Patients and Methods: Between August 1995 and June 2002, 2,021 previously untreated children with FH or anaplastic Wilms tumor, clear-cell sarcoma of the kidney (CCSK) or malignant rhabdoid tumor of the kidney (RTK), were treated with stage- and histology-specific therapy. Their tumors were assayed for LOH for polymorphic DNA markers on chromosomes 1p and 16q. Results: LOH for 1p or 16q was rarely observed in CCSK (n = 90) or RTK (n = 22). The relative risk (RR) of relapse for patients with FH stage I to IV tumors with LOH, stratified by stage, was 1.56 for LOH 1p (P = .01) and 1.49 for LOH 16q (P = .01), whereas the RR of death was 1.84 (P = .03) and 1.44 (P = .15), respectively. When the effects of LOH for both regions were considered jointly among patients with stage I to II FH disease, the risks of relapse and death were increased for LOH 1p only (RR = 2.2, P = .02 for relapse; RR = 4.0, P = .02 for death), for LOH 16q only (RR = 1.9, P = .01 and RR = 1.4, P = .60) and for LOH for both regions (RR = 2.9, P = .001 and RR = 4.3, P = .01) in comparison with patients with LOH at neither locus. The risks of relapse and death for patients with stage III to IV FH tumors were increased only with LOH for both regions (RR = 2.4, P = .01 and RR = 2.7, P = .04). Conclusion: Tumor-specific LOH for both chromosomes 1p and 16q identifies a subset of FH Wilms tumor patients who have a significantly increased risk of relapse and death. LOH for these chromosomal regions can now be used as an independent prognostic factor together with disease stage to target intensity of treatment to risk of treatment failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Cloning: A Laboratory Manual
Sambrook, J., Fritsch, E., & Maniatis, T. (1989) · UCLA - Biblioteca de Ciencias de la Salud · Cited by 133,589
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity
Feinberg, A. P., & Vogelstein, B. (1983) · Analytical Biochemistry · doi:10.1016/0003-2697(83)90418-9 · Cited by 24,887
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Treatment of Wilms' tumor. Results of the third national Wilms' tumor study
D'angio, G. J., Breslow, N., Beckwith, J. B., Evans, A., Baum, E., Delorimier, A., Fernbach, D., Hrabovsky, E., Jones, B., Kelalis, P., et al. (1989) · Cancer · doi:10.1002/1097-0142(19890715)64:2<349::aid-cncr2820640202>3.0.co;2-q · Cited by 681
Self-citationThe treatment of Wilms' tumor. Results of the national Wilms' tumor study
D'Angio, G. J., Evans, A. E., Breslow, N., Beckwith, B., Bishop, H., Feigl, P., Goodwin, W., Leape, L. L., Sinks, L. F., Sutow, W., et al. (1976) · Cancer · doi:10.1002/1097-0142(197608)38:2<633::aid-cncr2820380203>3.0.co;2-s · Cited by 457
Self-citationThe treatment of Wilms' Tumor: Results of the second national Wilms' Tumor study
D'Angio, G. J., Evans, A., Breslow, N., Beckwith, B., Bishop, H., Farewell, V., Goodwin, W., Leape, L., Palmer, N., Sinks, L., et al. (1981) · Cancer · doi:10.1002/1097-0142(19810501)47:9<2302::aid-cncr2820470933>3.0.co;2-k · Cited by 454
Self-citation
Cited by
Wegert, J., Ishaque, N., Vardapour, R., Geörg, C., Gu, Z., Bieg, M., Ziegler, B., Bausenwein, S., Nourkami, N., Ludwig, N., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.01.002 · Cited by 302
O'Leary, M., Krailo, M., Anderson, J. R., & Reaman, G. H. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.07.008 · Cited by 293
The genetic changes of Wilms tumour
Treger, T. D., Chowdhury, T., Pritchard-Jones, K., & Behjati, S. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0112-0 · Cited by 257
Zeng, X., & Rao, M. S. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.09.017 · Cited by 92
Genomic imbalances pinpoint potential oncogenes and tumor suppressors in Wilms tumors
Krepischi, A. C. V., Maschietto, M., Ferreira, E. N., Silva, A. G., Costa, S. S., da Cunha, I. W., Barros, B. D. F., Grundy, P. E., Rosenberg, C., & Carraro, D. M. (2016) · Molecular Cytogenetics · doi:10.1186/s13039-016-0227-y · Cited by 56
Self-citation
Metadata
- Authors
- Grundy, P. E., Breslow, N. E., Li, S., Perlman, E., Beckwith, J. B., Ritchey, M. L., Shamberger, R. C., Haase, G. M., D'Angio, G. J., Donaldson, M., Coppes, M. J., Malogolowkin, M., Shearer, P., Thomas, P. R. M., Macklis, R., Tomlinson, G., Huff, V., & Green, D. M.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-10-10
- Volume
- 23
- Issue
- 29
- Pages
- 7312-7321
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2171862017
- Cited by
- 480
- References
- 17
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Loss of Heterozygosity for Chromosomes 1p and 16q Is an Adverse Prognostic Factor in Favorable-Histology Wilms Tumor: A Report From the National Wilms Tumor Study Group. https://app.cochat.ai/papers/10.1200/jco.2005.01.2799
- The paper
- Grundy, P. E., Breslow, N. E., Li, S., Perlman, E., Beckwith, J. B., Ritchey, M. L., Shamberger, R. C., Haase, G. M., D'Angio, G. J., Donaldson, M., Coppes, M. J., Malogolowkin, M., Shearer, P., Thomas, P. R. M., Macklis, R., Tomlinson, G., Huff, V., & Green, D. M. (2005). Loss of Heterozygosity for Chromosomes 1p and 16q Is an Adverse Prognostic Factor in Favorable-Histology Wilms Tumor: A Report From the National Wilms Tumor Study Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.01.2799
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.